Clinical trial · Observational
Prevalence of H. Pylori in Stomach Cancers in the West Indies
NCT07233447CI-TRIAL-00097431PyloCaGerecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The incidence and mortality of stomach cancer are higher in the French West Indies than in mainland France. The prevalence of H. pylori infection associated with this cancer remains unknown in these populations. The main objective of the study is to estimate the prevalence of H. Pylori detected by immunohistochemistry in patients newly diagnosed with cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Oncology Epidemiology | — | UNRESOLVED | — |
| Risk Factors | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- detection of H. Pylori in immunohistochemistry
- timeFrame
- Baseline
- description
- Detection of Helicobacter pylori will be performed by immunohistochemistry (IHC) on gastric biopsy samples collected at inclusion. The procedure aims to identify the presence of H. pylori antigens within the gastric mucosa using specific antibodies. The test will be conducted in a certified pathology laboratory according to standard diagnostic protocols. Results will be reported as positive or negative for H. pylori infection.
Secondary outcomes (1)
- measure
- positivity of anti H. Hylori serology by Elisa test
- timeFrame
- Baseline
- description
- Positivity of anti-Helicobacter pylori serology determined by ELISA test performed on serum samples collected at inclusion. Results will be reported as positive or negative for H. pylori antibodies.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient over 18 years of age residing in Guadeloupe for more than 6 months and with a primary diagnosis of gastric cancer * Patient having read the information note and having signed the consent to participate in the study * Patient with social security coverage. Exclusion Criteria: * Refusal to participate. * Patient who could not answer the questionnaires * Patient not affiliated to a social security scheme * Patient under legal protection (judicial safeguard, guardianship, curatorship, etc.) * Pregnant or breastfeeding woman * Subject participating in another research study that includes an exclusion period still ongoing at the time of pre-inclusion
References
Publications (0)
Data not yet available
No reference posted for this study.